Adipotide

What Adipotide does

Adipotide is designed to destroy blood vessels that feed white fat. It reduced weight in rodents and monkeys, but also injured monkey kidneys. One human phase 1 trial enrolled four men and ended without posted results. It has no FDA approval or established human dosing schedule. Online use reports cannot show that it works or is safe.

• In animal studies in monkeys, it reduced body fat and weight. (animal)
• In animal studies in rodents, most of the weight loss came from eating less. (animal)
• In obese mice, blood sugar handling improved even before weight came off. (animal)
• A few people report fat loss, but often while dieting or taking other weight-loss drugs, so the cause is unclear. (Reported by users)

Uses in the sources

• People report using it for fat loss. Published efficacy data are from animals; the human trial has no results. (Reported by users) (source)
• Registered for dose-finding in men with metastatic prostate cancer and obesity; no cancer or weight outcomes were reported. (Studied in a trial) (source)

Adipotide dosage

Typical reported dose: 1 mg once a day in 30-day cycles

• 1 mg daily, 30-day cycles: 1 mg once daily on days 1–30 once daily, under the skin. Reported by users, rare report. Studied in: Adults self-reporting use online; identity and doses unverified. (source)
• 2.5 mg daily, 25 days: 2.5 mg daily on days 1–25 once daily, under the skin. Reported by users, rare report. Studied in: Adults self-reporting use online; identity and doses unverified. (source)
• 1 to 3 mg during a 28-day cycle: Days 1–1 or 1–2: 1 mg daily; then 3 mg daily, then 3 mg once daily through day 28 once daily, under the skin. Reported by users, rare report. Studied in: Adults self-reporting use online; identity and doses unverified. (source)
• 500 mcg morning and night: 500 mcg each morning and night on days 1–30 twice daily, under the skin. Reported by users, rare report. Studied in: Adults self-reporting use online; identity and doses unverified. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to mix Adipotide

Comes as: Community-reported powder vials for mixing and injection.

Mixed with: Bacteriostatic water is reported by one user; compatibility and stability are unvalidated..

Common vial sizes: 2, 10 mg. Common water amounts: 1 mL.

• One report describes 2 mg with 1 mL water; these are anecdotes, not a standard formulation.
• A separate report describes 10 mg/3 mL; the exact added-water volume is unstated.
• Syringe units measure volume, not mass; conversion needs the actual concentration.
• No approved storage label, mixing instructions or beyond-use date was found.

Before mixing: One user reports freezer storage; no validated temperature range or shelf life was found.

After mixing: A user reports keeping the mixed vial in a fridge. No adipotide-specific refrigerated shelf life is established.

Adipotide side effects and risks

Reported side effects

• Kidney tubular injury and higher creatinine: Human rate unknown. In lean monkeys at 0.43 mg/kg, creatinine rose sporadically in 2/5., serious. Stop use and seek prompt kidney assessment; symptoms may be absent. (source)
• Potassium and phosphate loss: Dose related changes in monkeys; no human event rates., serious. Check electrolytes and kidney function; do not self-correct with large potassium doses. (source)
• Sugar or protein leaking into urine: Mild–marked urine glucose and mild–moderate protein in monkeys; human rate unknown., serious. Urine testing can reveal injury even when you feel well. (source)
• More urination and dehydration: Observed in monkeys; dehydration was noted at the highest doses., moderate. Prompt assessment for thirst, dizziness or changing urine output. (source)
• Burning, itching, lumps or welts at injection sites: Several online accounts; no denominator or verified human rate., moderate. Persistent or worsening swelling needs clinical review. (source)
• Flushing, fatigue or headache: One online log; no clinical incidence estimate., mild. New or persistent symptoms warrant review rather than dose escalation. (source)
• Reduced appetite: Observed in rodents and monkeys and reported online; human rate unknown., moderate. Track intake and hydration; unexplained rapid weight loss needs assessment. (source)

Stop and get help if

• Much less urine, swollen legs, vomiting, severe thirst or new breathlessness: Stop exposure and seek urgent medical assessment for possible kidney injury.
• New confusion, severe drowsiness, collapse or trouble breathing: Seek emergency care now; do not wait for a routine blood test.
• Swollen tongue or throat, wheezing or fainting after an injection: Call emergency services now for possible severe allergy.
• A new rise in creatinine or new glucose/protein in urine, even without pain: Stop exposure and arrange prompt clinician review; painless injury is possible.

Who should avoid it

• pregnant: Pregnancy safety is unknown. No women were enrolled in the only human trial.
• breastfeeding: Milk transfer and infant safety are unknown; no breastfeeding data were found.
• tryingToConceive: Fertility and embryo safety are unknown. The human trial required contraception.
• under18: The trial excluded anyone under 18; no pediatric safety data were found.
• kidneyDisease: Kidney tubular injury occurred in monkeys. The human trial required adequate kidney function.
• other: Dehydration can worsen kidney injury; adipotide caused urine and electrolyte losses in monkeys.
• other: The trial excluded uncorrected blockage affecting both kidneys or a solitary kidney.
• uncontrolledBloodPressure: The trial excluded chronic uncontrolled blood pressure because of possible existing kidney damage.
• heartCondition: Recent heart attack, unstable angina and severe heart failure were excluded from the human trial.
• liverDisease: The trial excluded chronic liver disease with scarring or impaired liver function.
• diabetes: Uncontrolled diabetes was excluded. Animal glucose changes make medication review important.
• eatingDisorderHistory: Food intake fell in animal studies. With no human safety data, appetite and weight effects are a concern.
• activeCancer: The only human trial involved prostate cancer and has no results. Any use needs oncology review.
• surgeryPlanned: Kidney injury risk warrants review before surgery, fasting or exposure to other kidney-stressing drugs.
• testedAthlete: S0 of the 2026 WADA List covers unapproved substances at all times; this applies to adipotide.

Interactions

• NSAID pain medicines: The trial barred ongoing NSAIDs and required avoidance through 30 days after dosing. Aspirin ≤81 mg/day was excepted; review prescribed aspirin first.
• Strongly kidney-toxic medicines: The trial excluded IV vancomycin, aminoglycosides and other strongly kidney-toxic drugs. Added kidney harm is a concern.
• Insulin and sulfonylureas: Potential low blood sugar if insulin sensitivity or food intake changes. This is an animal-based precaution; no human interaction study exists.
• Diuretics and kidney-sensitive blood-pressure drugs: Fluid loss may increase kidney risk. This is a general kidney precaution, not a measured adipotide interaction; review medicines before changing them.
• Other weight-loss peptides: Stacks are reported online, without controlled combination safety data. Animal kidney harm and reduced intake remain concerns.
• Purported kidney-protection supplements or peptides: Forum users discuss protection, but no adipotide study establishes that these prevent kidney injury.

Product quality risks

• No published test-buy study of online adipotide was found; its real-world purity and dose accuracy are unknown.
• In three online semaglutide samples, purity was 7%–14% and drug content 29%–39% above label. This is indirect evidence, not adipotide testing.
• One semaglutide sample contained 8.95 EU/mg endotoxin despite no viable microbes detected. A sterility result alone misses this risk.
• TGA reports poorly labelled unapproved peptide vials with uncertain ingredients, manufacturing and sterility.

What to expect

One registered phase 1 trial enrolled four men; no results posted. Seven animal study entries cover five papers, with three separate monkey cohorts.

Key studies

• Terminated phase 1: four participants: Four enrolled; the trial ended in 2019 without public results. (source)
• White-fat targeting in mice: Targeting fat blood vessels reduced body fat in mice. (source)
• Reduced eating in obese rodents: Reduced eating explained most weight loss in these rodent experiments. (source)
• Monkey dose-finding: Weight fell as dose rose, alongside kidney changes. (source)
• Four-week monkey efficacy study: Fat and weight fell in monkeys; kidney safety remained a concern. (source)
• Kidney toxicity in lean monkeys: Kidney injury occurred even at doses used for monkey weight-loss experiments. (source)

Adipotide FAQ

• Is Adipotide FDA-approved? No FDA-approved product or label found. A research-use label is not drug approval. No adipotide-specific PCAC decision or warning letter was located.
• How do people take it? Under the skin, once daily. Author reports two 30-day cycles; break length was not specified. 30 days per cycle. Source: reported by users, not an established dose.
• What's the difference between Adipotide and AOD-9604? Adipotide: a fat-blood-vessel targeting peptide with monkey weight-loss data and kidney toxicity. AOD-9604: a growth-hormone fragment whose largest obesity trial failed to show meaningful weight loss. Why people pair them: one user combined them hoping for more fat loss and improved insulin sensitivity.
• Can I take it with AOD-9604? One user combined them hoping for more fat loss and improved insulin sensitivity. No human trial has tested the combination; benefit and kidney safety are unknown. Source: reported by users. Ask a doctor before combining anything.
• Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Application of S0 for unapproved substances; adipotide is not individually named. Effective January 1, 2026.
• How long does a mixed vial last? A user reports keeping the mixed vial in a fridge. No adipotide-specific refrigerated shelf life is established.